MGMitchell J. George

Mitchell J. George

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mitchell J. George has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Brijesh S. Gill

    Department of Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas

    5 shared publications
  • Charles E. Wade

    Department of Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas

    4 shared publications
  • Charles S. Cox

    Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas

    4 shared publications
  • Charles E. Wade

    Center for Translational Injury Research, The University of Texas Health Science Center, Houston, TX 77030, USA

    3 shared publications
  • Kevin R. Aroom

    Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas

    3 shared publications
  • Akiko Tanaka

    McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth)

    2 shared publications

Latest Publications

  • An Analysis of Sex-Based Outcomes Following Transcarotid Artery Revascularization

    by Regina Husman, Akiko Tanaka, Mitchell George, Tommaso Cambiaghi, Samuel D. Leonard, Raghu L. Motaganahalli, Andres Fajardo, S. Keisin Wang

    Objective: Several studies suggest that females have higher perioperative adverse events and decreased benefit from carotid artery revascularization with transfemoral carotid artery stenting and carotid endarterectomy (CEA) compared to males. However, there are limited data of sex-based outcomes for transcarotid artery revascularization (TCAR). Methods: A retrospective review of prospectively maintained system-wide TCAR databases was performed between December 2015-January 2022. Patients who underwent TCAR were stratified based on sex. Relevant demographics, medical conditions, anatomical characteristics, intra- and postoperative courses, and adverse events were captured. Results: 729 patients underwent TCAR, 486 (66.6%) male and 243 (33.3%) female. Males were more likely to be diagnosed with coronary artery disease (56.9% vs 47.7%, P<.01) and were active smokers (30.4% vs 21.4%, P < .01). Age, symptomatic status, BMI, hypertension, hyperlipidemia, diabetes mellitus, arrhythmia, chronic obstructive pulmonary disease, history of myocardial infarction, heart failure with reduced ejection fraction .99), ipsilateral stroke (1.9% vs 3.3%, P = .29), stent thrombosis (.4% vs .8%, P > .99), myocardial infarction (0% vs 0%, P > .99) and death (1.2% vs 1.2%, P > .99). In follow-up, no significant difference was found in reintervention, ipsilateral stroke, contralateral stroke, myocardial infarction, in-stent restenosis >50%, stent thrombosis, and death. Conclusions: Males and females did not have a statistically significant difference in outcomes when comparing ipsilateral stroke, in-stent thrombosis, conversion to CEA, and death after TCAR. However, our cohort comprised predominantly male patients and may conceal statistical significance as the females in our cohort did have a higher tendency toward developing complications. Future studies with a larger female cohort should be conducted to determine whether there is a true disparity of outcomes between the males and females undergoing TCAR.


  • Dual Institutional Experience with Transcarotid Artery Revascularization

    by Mitchell J George, Regina Husman, Hanaa Dakour-Aridi, Akiko Tanaka, Mackenzie Madison, Raghu Motaganahalli, Katherin Leckie, S Keisin Wang

    Introduction: Transcarotid artery revascularization (TCAR) is a hybrid open and endovascular technique to treat carotid stenosis. The purpose of this study is to present a large cohort of patients who underwent TCAR at 2 high-volume TCAR health systems. Methods: This study was a retrospective chart review of all instances of TCAR within the Memorial Hermann Health System and Indiana University Health, from December 2015-January 2022, using the ENROUTE Neuroprotection Device (Silk Road Medical, Sunnyvale, CA). We report patient demographics, intraoperative metrics, 30-day results and long-term results. Results: In all, 750 patients underwent TCAR in the designated time period. Average patient age was 73 years, with 68% being male. Overall, 53.9% of patients had coronary artery disease, 45.4% had diabetes, and 36.9% were symptomatic. Technical success was achieved in 98.8% of patients with conversion to open endarterectomy in 1.1%. Average reverse flow time was 9.1 minutes with length of stay greater than 1 day 38%. Ipsilateral stroke rate within 30 days was 2.3% and long-term cumulative stroke rate was 3.0%. Death within 30 days occurred in 1.2% of patients and in 5.9% over long-term follow up. In all, 1% of patients required reintervention. Conclusions: TCAR is a safe and effective treatment modality for carotid artery stenotic disease. Its outcomes are similar to historical results associated with carotid endarterectomy, long considered the gold standard.


  • 3D printing in aortic endovascular therapies

    by Mitchell J. George, Marina Dias-Neto, Emanuel Ramos Tenorio, Max A. Skibber, Jonathan M. Morris, Gustavo S. Oderich

    Article: 3D printing in aortic endovascular therapies: a review - The Journal of Cardiovascular Surgery 2022 Jul 13 - Minerva Medica - Journals


  • Open Access

    Microelectromechanical System Measurement of Platelet Contraction: Direct Interrogation of Myosin Light Chain Phosphorylation

    by Mitchell J. George, Julia Litvinov, Kevin Aroom, Leland J. Spangler, Henry Caplan, Charles E. Wade, Charles S. Cox, Brijesh S. Gill

    Myosin Light Chain (MLC) regulates platelet contraction through its phosphorylation by Myosin Light Chain Kinase (MLCK) or dephosphorylation by Myosin Light Chain Phosphatase (MLCP). The correlation between platelet contraction force and levels of MLC phosphorylation is unknown. We investigate the relationship between platelet contraction force and MLC phosphorylation using a novel microelectromechanical (MEMS) based clot contraction sensor (CCS). The MLCK and MLCP pair were interrogated by inhibitors and activators of platelet function. The CCS was fabricated from silicon using photolithography techniques and force was validated over a range of deflection for different chip spring constants. The force of platelet contraction measured by the clot contraction sensor (CCS) was compared to the degree of MLC phosphorylation by Western Blotting (WB) and ELISA. Stimulators of MLC phosphorylation produced higher contraction force, higher phosphorylated MLC signal in ELISA and higher intensity bands in WB. Inhibitors of MLC phosphorylation produced the opposite. Contraction force is linearly related to levels of phosphorylated MLC. Direct measurements of clot contractile force are possible using a MEMS sensor platform and correlate linearly with the degree of MLC phosphorylation during coagulation. Measured force represents the mechanical output of the actin/myosin motor in platelets regulated by myosin light chain phosphorylation.


  • A Novel Platelet Function Assay for Trauma

    by Mitchell J. George, Kevin R. Aroom, Charles E. Wade, Charles S. Cox, Brijesh S. Gill


  • Open Access

    Procoagulant in vitro effects of clinical cellular therapeutics in a severely injured trauma population

    by Mitchell J. George, Karthik Prabhakara, Naama E. Toledano-Furman, Brijesh S. Gill, Charles E. Wade, Bryan A. Cotton, Andrew P. Cap, Scott D. Olson, Charles S. Cox

    Clinical trials in trauma populations are exploring the use of clinical cellular therapeutics (CCTs) like human mesenchymal stromal cells (MSC) and mononuclear cells (MNC). Recent studies demonstrate a procoagulant effect of these CCTs related to their expression of tissue factor (TF). We sought to examine this relationship in blood from severely injured trauma patients and identify methods to reverse this procoagulant effect. Human MSCs from bone marrow, adipose, and amniotic tissues and freshly isolated bone marrow MNC samples were tested. TF expression and phenotype were quantified using flow cytometry. CCTs were mixed individually with trauma patients’ whole blood, assayed with thromboelastography (TEG), and compared with healthy subjects mixed with the same cell sources. Heparin was added to samples at increasing concentrations until TEG parameters normalized. Clotting time or R time in TEG decreased relative to the TF expression of the CCT treatment in a logarithmic fashion for trauma patients and healthy subjects. Nonlinear regression curves were significantly different with healthy subjects demonstrating greater relative decreases in TEG clotting time. In vitro coadministration of heparin normalized the procoagulant effect and required dose escalation based on TF expression. TF expression in human MSC and MNC has a procoagulant effect in blood from trauma patients and healthy subjects. The procoagulant effect is lower in trauma patients possibly because their clotting time is already accelerated. The procoagulant effect due to MSC/MNC TF expression could be useful in the bleeding trauma patient; however, it may emerge as a safety release criterion due to thrombotic risk. The TF procoagulant effect is reversible with heparin. Significance statement Stem cells are currently under investigation as a treatment for sequela of trauma like brain or lung injury. However, stem cells express tissue factor (TF) that causes rapid blood clotting. It is demonstrated that stem cells make blood from trauma patients, which clot faster. A potential antidote to this effect is heparin, a common and inexpensive blood thinner. It is believed that stem cells used in trauma studies should be risk-stratified based on their TF expression.


  • Open Access

    Clinical Cellular Therapeutics Accelerate Clot Formation

    by Mitchell J. George, Karthik Prabhakara, Naama E. Toledano-Furman, Yao-Wei Wang, Brijesh S. Gill, Charles E. Wade, Scott D. Olson, Charles S. Cox

    Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731–739


  • The effect of damage control laparotomy on major abdominal complications: A matched analysis

    by Mitchell J. George, Sasha D. Adams, Michelle K. McNutt, Joseph D. Love, Rondel Albarado, Laura J. Moore, Charles E. Wade, Bryan A. Cotton, John B. Holcomb, John A. Harvin


  • Platelet biomechanics, platelet bioenergetics, and applications to clinical practice and translational research

    by Mitchell J. George, James Bynum, Prajeeda Nair, Andrew P. Cap, Charles E. Wade, Charles S. Cox, Brijesh S. Gill

    The purpose of this review is to explore the relationship between platelet bioenergetics and biomechanics and how this relationship affects the clinical interpretation of platelet function devices. Recent experimental and technological advances highlight platelet bioenergetics and biomechanics as alternative avenues for collecting clinically relevant data. Platelet bioenergetics drive energy production for key biomechanical processes like adhesion, spreading, aggregation, and contraction. Platelet function devices like thromboelastography, thromboelastometry, and aggregometry measure these biomechanical processes. Platelet storage, stroke, sepsis, trauma, or the activity of antiplatelet drugs alters measures of platelet function. However, the specific mechanisms governing these alterations in platelet function and how they relate to platelet bioenergetics are still under investigation.


  • Energetics of Clot Formation: A Direct Measurement

    by Mitchell J. George, Kevin R. Aroom, Max A. Skibber, Tushar Sharma, Charles E. Wade, Charles S. Cox, Brijesh Gill